The NIH, along with 10 biopharma companies and eight non-profit organizations, have formed the Accelerating Medicines Partnership
The NIH, along with 10 biopharma companies and eight non-profit organizations, have formed the Accelerating Medicines Partnership (AMP) in the hopes of accelerating biomarker identification and drug targets in four diseases—Alzheimer's, Type II diabetes, rheumatoid arthritis and lupus—through data sharing. At the foundation of the partnership is the agreement that the data and analyses generated will be made publicly available to the broad biomedical community.
The AMP partners, along with the NIH include FDA, as well as biopharma sponsors AbbVie, Biogen, BMS, GSK, J&J, Lilly, Merck, Pfizer, Sanofi and Takeda. Major disease associations include the Alzheimer’s Association, USAgainstAlzheimer’s, American Diabetes Association, Lupus Foundation of America, and the Rheumatology Research Foundation. All partners have developed research plans and are sharing costs, expertise, and resources in an integrated governance structure. The three- to five-year, milestone-driven pilot projects in these disease areas could set the stage for broadening AMP to other diseases and conditions.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.